MeSH term
Frequency | Condition_Probility | Animals | 38 | 0.0 |
Humans | 311 | 0.0 |
Comparative Study | 28 | 0.0 |
*DNA Methylation | 27 | 4.0 |
DNA, Neoplasm/*genetics | 3 | 1.0 |
Disease Progression | 20 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 13 | 0.0 |
Middle Aged | 111 | 0.0 |
Precancerous Conditions/*genetics | 2 | 7.0 |
*Promoter Regions (Genetics) | 6 | 0.0 |
Prospective Studies | 6 | 0.0 |
Protein p16/*genetics | 54 | 57.0 |
Research Support, Non-U.S. Gov't | 228 | 0.0 |
Risk Factors | 16 | 0.0 |
Cyclin-Dependent Kinases/*genetics | 14 | 21.0 |
Dysplastic Nevus Syndrome/*genetics/pathology | 2 | 100.0 |
*Genes, p16 | 47 | 48.0 |
Melanoma/*genetics/pathology | 7 | 25.0 |
*Mutation | 27 | 0.0 |
*Proto-Oncogene Proteins | 29 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 63 | 0.0 |
Skin Neoplasms/*genetics/pathology | 6 | 10.0 |
Cell Division | 10 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Loss of Heterozygosity | 41 | 4.0 |
Mutation | 49 | 0.0 |
Polymerase Chain Reaction | 50 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Protein p16/metabolism | 6 | 10.0 |
Survival Analysis | 18 | 0.0 |
Australia | 5 | 2.0 |
Genes, p16 | 28 | 28.0 |
*Genetic Predisposition to Disease | 12 | 1.0 |
Melanoma/epidemiology/*genetics | 9 | 60.0 |
United States | 2 | 0.0 |
Variation (Genetics) | 5 | 0.0 |
Alleles | 21 | 0.0 |
Child | 30 | 0.0 |
*Chromosome Deletion | 12 | 1.0 |
In Situ Hybridization, Fluorescence | 14 | 0.0 |
Prognosis | 26 | 0.0 |
Adult | 104 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Gene Deletion | 27 | 1.0 |
Male | 141 | 0.0 |
Protein p16/genetics/*metabolism | 4 | 22.0 |
Protein p53/metabolism | 3 | 0.0 |
Ultraviolet Rays | 2 | 0.0 |
p14ARF Protein/genetics/*metabolism | 2 | 22.0 |
Aged | 86 | 0.0 |
Immunohistochemistry | 19 | 0.0 |
Risk | 4 | 0.0 |
Sequence Analysis, DNA | 10 | 0.0 |
Base Sequence | 30 | 0.0 |
DNA, Neoplasm | 4 | 3.0 |
Female | 142 | 0.0 |
Genetic Predisposition to Disease | 26 | 1.0 |
*Germ-Line Mutation | 16 | 3.0 |
Melanoma/*genetics | 62 | 41.0 |
Molecular Sequence Data | 36 | 0.0 |
Mutation, Missense | 4 | 0.0 |
Pedigree | 41 | 0.0 |
Protein p16/genetics | 17 | 20.0 |
Tumor Suppressor Proteins/*genetics | 2 | 1.0 |
p14ARF Protein/*genetics | 7 | 28.0 |
Aged, 80 and over | 30 | 0.0 |
Cell Cycle | 8 | 0.0 |
Codon | 4 | 0.0 |
DNA Mutational Analysis | 40 | 0.0 |
Exons | 14 | 0.0 |
*Genes, p53 | 5 | 1.0 |
Homozygote | 12 | 0.0 |
Models, Genetic | 5 | 0.0 |
Polymorphism, Genetic | 13 | 0.0 |
Promoter Regions (Genetics) | 17 | 0.0 |
Protein p53/biosynthesis | 2 | 1.0 |
Sulfites/pharmacology | 2 | 6.0 |
Chromosomes, Human, Pair 9/*genetics | 18 | 16.0 |
*Gene Deletion | 22 | 2.0 |
Gene Dosage | 5 | 1.0 |
Bladder Neoplasms/*genetics | 3 | 3.0 |
Carcinoma, Transitional Cell/genetics | 2 | 28.0 |
Chromosome Aberrations | 6 | 1.0 |
Chromosome Deletion | 10 | 1.0 |
Chromosome Painting | 3 | 6.0 |
Gene Expression | 4 | 0.0 |
*Genes, Tumor Suppressor | 14 | 1.0 |
Genetic Markers/genetics | 3 | 0.0 |
Loss of Heterozygosity/genetics | 10 | 7.0 |
Tumor Cells, Cultured | 47 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Adolescent | 41 | 0.0 |
Australia/epidemiology | 2 | 3.0 |
Case-Control Studies | 8 | 0.0 |
Melanoma/*epidemiology/etiology/genetics | 2 | 100.0 |
Sunlight/adverse effects | 2 | 10.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
*Cell Cycle Proteins | 18 | 1.0 |
Enzyme Inhibitors | 3 | 3.0 |
Genotype | 16 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Transfection | 9 | 0.0 |
Family Health | 13 | 1.0 |
Nevus/genetics | 2 | 100.0 |
Skin Neoplasms/*genetics | 32 | 26.0 |
Age of Onset | 4 | 0.0 |
Germ-Line Mutation | 12 | 3.0 |
Pancreatic Neoplasms/*genetics/pathology | 2 | 5.0 |
Phenotype | 18 | 0.0 |
*Genetic Markers | 3 | 0.0 |
Signal Transduction | 3 | 0.0 |
Amino Acid Sequence | 14 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Chromosomes, Human, Pair 9/genetics | 16 | 13.0 |
DNA, Neoplasm/genetics | 15 | 1.0 |
Gene Amplification | 7 | 0.0 |
*Genes, abl | 2 | 7.0 |
Age Factors | 8 | 0.0 |
Child, Preschool | 15 | 0.0 |
CpG Islands/genetics | 7 | 5.0 |
Amino Acid Substitution | 3 | 0.0 |
DNA, Neoplasm/chemistry/genetics | 7 | 5.0 |
Gene Frequency | 2 | 0.0 |
Italy | 5 | 0.0 |
Polymorphism, Single-Stranded Conformational | 36 | 1.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Astrocytoma/*genetics/pathology | 2 | 8.0 |
Brain Neoplasms/*genetics/pathology | 5 | 7.0 |
Chromosomes, Human, Pair 1/*genetics | 3 | 1.0 |
Cyclin-Dependent Kinases/genetics | 15 | 25.0 |
DNA, Neoplasm/analysis | 14 | 1.0 |
Molecular Biology | 2 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Neoplasm Staging | 10 | 0.0 |
Oligodendroglioma/*genetics/pathology | 2 | 16.0 |
Protein p53/genetics | 7 | 4.0 |
Receptor, Epidermal Growth Factor/genetics | 6 | 5.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
Cell Cycle Proteins/*genetics/metabolism | 2 | 3.0 |
Chi-Square Distribution | 2 | 0.0 |
Protein p16/*genetics/metabolism | 9 | 45.0 |
*Tumor Suppressor Proteins | 31 | 2.0 |
Ependymoma/*genetics/pathology | 2 | 40.0 |
Methylation | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 21 | 0.0 |
Blotting, Southern | 9 | 0.0 |
Blotting, Western | 7 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Gene Silencing | 8 | 2.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Bladder Neoplasms/*genetics/pathology | 2 | 5.0 |
Chromosome Mapping | 24 | 0.0 |
*Chromosomes, Human, Pair 9 | 17 | 6.0 |
DNA Methylation | 23 | 3.0 |
Genes, Tumor Suppressor | 13 | 1.0 |
Microsatellite Repeats | 23 | 1.0 |
Neoplasm Recurrence, Local/genetics | 2 | 9.0 |
Sequence Deletion | 7 | 0.0 |
Tumor Suppressor Proteins/genetics | 6 | 8.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Haplotypes | 6 | 0.0 |
Point Mutation | 12 | 0.0 |
Polymerase Chain Reaction/methods | 7 | 0.0 |
Germ-Line Mutation/*genetics | 8 | 5.0 |
Head and Neck Neoplasms/*genetics/pathology | 2 | 6.0 |
Protein p16/analysis/*genetics | 3 | 50.0 |
CpG Islands | 4 | 1.0 |
Exons/genetics | 3 | 0.0 |
Protein p16/*physiology | 3 | 33.0 |
Cell Cycle Proteins/*genetics | 5 | 3.0 |
Genes, p53/*genetics | 5 | 1.0 |
Heterozygote | 6 | 0.0 |
Introns | 3 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Genetic Predisposition to Disease/*genetics | 4 | 1.0 |
Mutation/*genetics | 8 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Cell Differentiation | 2 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 9 | 0.0 |
Genes, myc/genetics | 2 | 2.0 |
Mice | 27 | 0.0 |
Mice, Inbred BALB C | 6 | 0.0 |
*Protein p16 | 2 | 5.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
*Loss of Heterozygosity | 7 | 1.0 |
Proteins/genetics | 5 | 0.0 |
Retinoblastoma Protein/*genetics | 5 | 11.0 |
DNA Mutational Analysis/methods | 4 | 1.0 |
*Founder Effect | 3 | 2.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Heterozygote Detection | 5 | 0.0 |
Neoplasms, Multiple Primary/*genetics | 9 | 22.0 |
3' Untranslated Regions | 2 | 1.0 |
5' Untranslated Regions/genetics | 2 | 1.0 |
Alternative Splicing | 3 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Physical Chromosome Mapping | 2 | 0.0 |
Sequence Deletion/*genetics | 2 | 1.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Disease Susceptibility | 4 | 0.0 |
G1 Phase | 4 | 1.0 |
Genetic Screening | 7 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Linkage (Genetics) | 6 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Age Distribution | 3 | 0.0 |
Cell Transformation, Neoplastic/genetics | 4 | 1.0 |
Genes, Retinoblastoma | 2 | 2.0 |
Genes, p53 | 10 | 2.0 |
*Nuclear Proteins | 12 | 0.0 |
Sex Distribution | 2 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Protein p16/genetics/physiology | 2 | 33.0 |
p14ARF Protein | 19 | 24.0 |
Genes, p16/*genetics | 31 | 70.0 |
Carrier Proteins/*genetics | 20 | 1.0 |
Chromosomes, Human, Pair 1 | 3 | 1.0 |
Chromosomes, Human, Pair 9 | 6 | 3.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 2 | 2.0 |
Cyclins/*genetics | 2 | 1.0 |
*Enzyme Inhibitors | 3 | 7.0 |
Proteins/*genetics | 12 | 0.0 |
DNA, Neoplasm/*analysis | 4 | 2.0 |
Introns/genetics | 2 | 0.0 |
Polymorphism, Genetic/genetics | 5 | 0.0 |
Adenocarcinoma/etiology/*genetics | 2 | 25.0 |
CpG Islands/*genetics | 2 | 2.0 |
Genes, Tumor Suppressor/genetics | 8 | 4.0 |
Neurofibroma/*genetics | 2 | 13.0 |
Immunoenzyme Techniques | 6 | 0.0 |
Genes, p16/genetics | 8 | 36.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
*Repressor Proteins | 3 | 0.0 |
Phosphoric Monoester Hydrolases/genetics | 13 | 17.0 |
Protein p53/analysis | 2 | 0.0 |
Chromosomes, Human, Pair 10 | 2 | 1.0 |
Cyclins/genetics | 3 | 2.0 |
Environment | 2 | 2.0 |
Nevus/*genetics | 2 | 33.0 |
*Point Mutation | 7 | 0.0 |
Valine/genetics | 2 | 2.0 |
Likelihood Functions | 5 | 2.0 |
Sweden | 4 | 1.0 |
English Abstract | 6 | 0.0 |
Radiation Dosage | 3 | 3.0 |
Ultraviolet Rays/*adverse effects | 3 | 6.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
Esophageal Neoplasms/*genetics/pathology | 2 | 6.0 |
Gene Expression Profiling | 2 | 0.0 |
Precancerous Conditions/genetics | 3 | 14.0 |
Adenocarcinoma/*genetics | 5 | 3.0 |
Pancreatic Neoplasms/*genetics | 5 | 5.0 |
Proto-Oncogenes | 4 | 2.0 |
Syndrome | 4 | 0.0 |
Pancreatic Neoplasms/epidemiology/*genetics/therapy | 2 | 100.0 |
United States/epidemiology | 6 | 1.0 |
*Gene Silencing | 3 | 1.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Protein p16/*metabolism | 4 | 12.0 |
Necrosis | 2 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
Spain | 3 | 0.0 |
DNA, Neoplasm/genetics/metabolism | 3 | 3.0 |
Genetic Markers | 12 | 0.0 |
Cluster Analysis | 2 | 1.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Genes, Tumor Suppressor/*genetics | 10 | 3.0 |
Gene Frequency/genetics | 2 | 0.0 |
Genes, ras/*genetics | 3 | 3.0 |
Chromosome Aberrations/*genetics | 2 | 1.0 |
In Situ Hybridization, Fluorescence/methods | 3 | 3.0 |
Inversion, Chromosome | 2 | 3.0 |
Kidney Neoplasms/*genetics/pathology | 3 | 4.0 |
Protein Binding | 2 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Astrocytoma/*genetics | 3 | 6.0 |
Brain Neoplasms/*genetics | 5 | 3.0 |
Transplantation, Heterologous | 2 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Protein p16/genetics/metabolism | 4 | 15.0 |
Protein p53/genetics/metabolism | 2 | 2.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Dysplastic Nevus Syndrome/genetics | 3 | 75.0 |
Germ-Line Mutation/genetics | 5 | 7.0 |
Cell Division/radiation effects | 2 | 4.0 |
Cell Line | 4 | 0.0 |
Enzyme Induction | 3 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 7 | 4.0 |
Genes, Suppressor | 2 | 6.0 |
Mouth Neoplasms/*genetics | 2 | 4.0 |
Gene Library | 2 | 0.0 |
*Alleles | 5 | 0.0 |
*Carrier Proteins | 2 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Genes, p53/genetics | 6 | 2.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Neoplasm Recurrence, Local/genetics/pathology | 2 | 20.0 |
Proto-Oncogene Proteins/genetics | 9 | 1.0 |
Transcription Factors/genetics | 3 | 0.0 |
Carrier Proteins/genetics | 3 | 0.0 |
Genes, ras/genetics | 2 | 1.0 |
Mice, Inbred DBA | 3 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Protein p16 | 23 | 15.0 |
Tumor Stem Cell Assay | 3 | 1.0 |
Dysplastic Nevus Syndrome/*genetics | 3 | 75.0 |
Netherlands | 2 | 1.0 |
*Gene Amplification | 3 | 0.0 |
Karyotyping | 6 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Neoplasm Proteins/genetics | 3 | 0.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
Neoplastic Syndromes, Hereditary/*genetics | 3 | 7.0 |
Nevus, Pigmented/genetics | 3 | 50.0 |
Chromosomes, Human, Pair 10/genetics | 3 | 3.0 |
Phosphoric Monoester Hydrolases/*genetics | 2 | 0.0 |
Dysplastic Nevus Syndrome/epidemiology/*genetics | 2 | 100.0 |
Lung Neoplasms/genetics | 2 | 3.0 |
Pancreatic Neoplasms/epidemiology/*genetics | 3 | 42.0 |
Retrospective Studies | 6 | 0.0 |
Skin Neoplasms/epidemiology/*genetics | 8 | 57.0 |
Binding Sites | 2 | 0.0 |
Glioblastoma/*genetics | 4 | 5.0 |
Mutagenesis | 2 | 0.0 |
Protein p53/*genetics | 3 | 1.0 |
Disease Models, Animal | 5 | 0.0 |
Immunoblotting | 3 | 0.0 |
Protein p16/genetics/immunology/*metabolism | 2 | 100.0 |
Retinoblastoma Protein/genetics/metabolism | 2 | 5.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 3 | 2.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Hela Cells | 3 | 0.0 |
Pilot Projects | 3 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
Genetic Heterogeneity | 4 | 1.0 |
Time Factors | 7 | 0.0 |
Molecular Biology/methods | 2 | 7.0 |
Mutation/genetics | 3 | 0.0 |
Cyclin D1/genetics | 2 | 3.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
*Genes, Retinoblastoma | 2 | 1.0 |
Predictive Value of Tests | 5 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Melanoma/genetics | 6 | 17.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Skin Neoplasms/genetics | 2 | 6.0 |
*Ultraviolet Rays | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Carrier Proteins/*genetics/metabolism | 4 | 1.0 |
Cell Line, Transformed | 3 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Clone Cells | 2 | 0.0 |
Rats | 5 | 0.0 |
*Chromosome Aberrations | 3 | 0.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Soft Tissue Neoplasms/*genetics | 2 | 7.0 |
Chromosomes, Human, Pair 17/genetics | 4 | 2.0 |
Mice, Nude | 4 | 0.0 |
Nasopharyngeal Neoplasms/*genetics | 2 | 9.0 |
Genetic Screening/*methods | 2 | 1.0 |
In Situ Hybridization, Fluorescence/*methods | 2 | 2.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 2 | 7.0 |
Brain Neoplasms/genetics | 2 | 11.0 |
Multiple Myeloma/*genetics | 2 | 4.0 |
Species Specificity | 2 | 0.0 |
Carcinoma, Small Cell/*genetics | 2 | 3.0 |
Chromosome Banding | 3 | 0.0 |
*Homozygote | 4 | 2.0 |
Lung Neoplasms/*genetics | 4 | 1.0 |
Hybrid Cells | 2 | 0.0 |
Lod Score | 5 | 0.0 |
Azacitidine/*analogs & derivatives/pharmacology | 2 | 2.0 |
Hydroxamic Acids/pharmacology | 2 | 1.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Receptor, Melanocortin, Type 1/*genetics | 3 | 20.0 |
Skin Pigmentation/genetics | 3 | 18.0 |
Penetrance | 2 | 1.0 |
Glioma/*genetics | 3 | 3.0 |
Glioma/*genetics/pathology | 2 | 6.0 |
Environmental Exposure | 2 | 1.0 |
Incidence | 5 | 0.0 |
Risk Assessment | 3 | 0.0 |
Prevalence | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Cyprinodontiformes/*genetics | 2 | 20.0 |
Phylogeny | 2 | 0.0 |
DNA Primers | 8 | 0.0 |
Protein Biosynthesis | 4 | 0.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Receptors, Melanocortin | 2 | 2.0 |
Astrocytoma/genetics | 3 | 12.0 |
Chromosomes, Human, Pair 19 | 2 | 1.0 |
Glioblastoma/genetics | 2 | 6.0 |
Survival Rate | 5 | 0.0 |
Linkage (Genetics)/*genetics | 3 | 1.0 |
Melanoma/genetics/*metabolism | 2 | 12.0 |
Head and Neck Neoplasms/*genetics | 4 | 5.0 |
Melanoma/etiology/*genetics/mortality | 2 | 100.0 |
Proto-Oncogene Proteins B-raf | 3 | 4.0 |
Proto-Oncogene Proteins c-raf/*genetics | 3 | 7.0 |
*Chromosome Mapping | 3 | 0.0 |
Carcinoma/*genetics | 2 | 1.0 |
Protein p53/genetics/*metabolism | 2 | 1.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 3 | 0.0 |
Azacitidine/analogs & derivatives/pharmacology | 2 | 8.0 |
DNA Modification Methylases/antagonists & inhibitors | 2 | 7.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Neoplasms/genetics | 3 | 2.0 |
Melanoma/etiology/*genetics | 4 | 44.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
p14ARF Protein/genetics | 3 | 14.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
Chromosomes, Human, Pair 19/genetics | 2 | 1.0 |
Neoplasm Recurrence, Local/*genetics | 3 | 18.0 |
*Alternative Splicing | 2 | 0.0 |
Genes, Retinoblastoma/*genetics | 2 | 4.0 |
RNA Splicing | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Crosses, Genetic | 2 | 0.0 |
Brain Neoplasms/*genetics/*pathology | 2 | 16.0 |
Cyclin-Dependent Kinases/analysis/*genetics | 2 | 50.0 |
Glioblastoma/*genetics/*pathology | 2 | 28.0 |
Purine-Nucleoside Phosphorylase/*genetics | 3 | 20.0 |
Infant | 8 | 0.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Protein Kinase Inhibitors | 3 | 2.0 |
Mesothelioma/*genetics | 2 | 10.0 |
RNA, Messenger/genetics | 3 | 0.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 2 | 2.0 |
Cell Division/genetics | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
Tumor Markers, Biological/analysis | 4 | 0.0 |
Loss of Heterozygosity/*genetics | 2 | 2.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Retinoblastoma Protein/metabolism | 3 | 0.0 |
Genome | 3 | 1.0 |
Sweden/epidemiology | 3 | 2.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
Combined Modality Therapy | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Neoplasm Transplantation | 2 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Melanoma/*genetics/metabolism | 2 | 14.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Blotting, Western/methods | 2 | 1.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Drug Combinations | 2 | 0.0 |
Ultraviolet Rays/adverse effects | 3 | 4.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Jews/*genetics | 2 | 1.0 |
DNA/metabolism | 4 | 0.0 |
Glial Fibrillary Acidic Protein/metabolism | 2 | 0.0 |
